The earnings call presented a mix of positive developments in revenue growth, cost reduction, and pipeline progress. However, challenges remain in RSV sales, international market performance, and competitive pressures in the COVID vaccine market.

Company Guidance

During Moderna's Q3 2024 earnings call, the company provided detailed financial guidance and updates on their operational strategy. They reported a revenue of $1.9 billion for the quarter, with a net income of $13 million, and ended with cash and investments totaling $9.2 billion. Moderna highlighted significant cost-saving measures, having reduced operating expenses by $500 million compared to the first quarter of 2024. They maintained their full-year product sales estimate of $3 billion to $3.5 billion, with an anticipated Q4 sales range of $0.8 billion to $1.3 billion. Additionally, Moderna's market share for COVID vaccines in the U.S. retail sector was approximately 40%, and they have been actively working to capture larger market shares in other sectors. The company also discussed its focus on long-term growth through a robust pipeline, aiming for up to 10 product approvals over the next three years, and emphasized ongoing efforts to improve COVID-19 vaccination rates through health care provider education and consumer campaigns.

Revenue and Cost Reductions

Moderna delivered $1.9 billion of revenue in Q3 2024. They reduced operating expenses by $500 million compared to Q1 2024, excluding a $1.4 billion resizing charge. Net income improved to $13 million from a loss of $3.6 billion in Q3 2023.

U.S. Market Success

Moderna achieved a 40% share of retail COVID vaccine doses in the U.S. and experienced an earlier launch for the 2024-2025 season that exceeded expectations.

Pipeline Advancements

Moderna reported positive Phase III data for its next-generation COVID vaccine, RSV vaccine, and combination flu-COVID vaccine. Plans to file for approval in 2024 for these products.

Executive Committee Expansion

Moderna expanded its executive committee by promoting internal talent and emphasizing integration of people, culture, and digital innovation.

---

Moderna (MRNA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MRNA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 20, 2025	2024 (Q4)	-2.78 / -	0.55	―	―	―
Nov 07, 2024	2024 (Q3)	-1.80 / 0.03	-9.53	100.31% (+9.56)
Aug 01, 2024	2024 (Q2)	-3.35 / -3.33	-3.62	8.01% (+0.29)
May 02, 2024	2024 (Q1)	-3.56 / -3.07	0.19	-1715.79% (-3.26)
Feb 22, 2024	2023 (Q4)	-0.99 / 0.55	3.61	-84.76% (-3.06)
Nov 02, 2023	2023 (Q3)	-1.93 / -9.53	2.53	-476.68% (-12.06)
Aug 03, 2023	2023 (Q2)	-3.94 / -3.62	5.24	-169.08% (-8.86)
May 04, 2023	2023 (Q1)	-1.75 / 0.19	8.58	-97.79% (-8.39)
Feb 23, 2023	2022 (Q4)	4.60 / 3.61	11.29	-68.02% (-7.68)
Nov 03, 2022	2022 (Q3)	3.30 / 2.53	7.7	-67.14% (-5.17)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

MRNA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 07, 2024	$51.81	$50.28	-2.95%
Aug 01, 2024	$119.22	$94.17	-21.01%
May 02, 2024	$111.46	$125.59	+12.68%
Feb 22, 2024	$87.59	$99.44	+13.53%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---